Compare · SGEN vs TWST
SGEN vs TWST
Side-by-side comparison of Seagen Inc. (SGEN) and Twist Bioscience Corporation (TWST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both SGEN and TWST operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- SGEN is the larger of the two at $23.34B, about 2.3x TWST ($10.04B).
- TWST has hit the wire 33 times in the past 4 weeks while SGEN has been quiet.
- SGEN has more recent analyst coverage (25 ratings vs 15 for TWST).
- Company
- Seagen Inc.
- Twist Bioscience Corporation
- Price
- $228.86-0.01%
- $151.63+7.80%
- Market cap
- $23.34B
- $10.04B
- 1M return
- -
- +75.54%
- 1Y return
- -
- +446.61%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2001
- 2018
- News (4w)
- 0
- 33
- Recent ratings
- 25
- 15
Seagen Inc.
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of metastatic urothelial cancers; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops Tisotumab Vedotin for metastatic cervical cancer and other solid tumors; ladiratuzumab vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and SpringWorks Therapeutics, Inc. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Twist Bioscience Corporation
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with ImmunoPrecise Antibodies Ltd.; Victorian Clinical Genetic Services; Vivlion GmbH; and Kyowa Kirin Pharmaceutical Research, Inc. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.
Latest SGEN
- Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight
- Alltrna Announces Updates to Its Board of Directors
- Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment
- How To Earn $500 A Month From Pfizer Stock
- Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
- SEC Form 15-12G filed by Seagen Inc.
- Baker Bros. Advisors Lp returned $10,248,908,740 worth of shares to the company (44,755,060 units at $229.00), closing all direct ownership in the company (SEC Form 4)
- SEC Form SC 13D/A filed by Seagen Inc. (Amendment)
- Himes Vaughn B returned $30,765,005 worth of shares to the company (134,345 units at $229.00), closing all direct ownership in the company (SEC Form 4)
- Simonian Nancy A returned $14,370,437 worth of shares to the company (62,753 units at $229.00), closing all direct ownership in the company (SEC Form 4)
Latest TWST
- Officer Cho Dennis sold $222,227 worth of shares (1,598 units at $139.07), decreasing direct ownership by 2% to 74,063 units (SEC Form 4) to satisfy withholding tax
- President and COO Finn Patrick John sold $562,661 worth of shares (4,046 units at $139.07), decreasing direct ownership by 2% to 210,802 units (SEC Form 4) (tax withholding)
- Chief Accounting Officer Werner Robert F. sold $213,255 worth of shares (1,523 units at $140.02), decreasing direct ownership by 3% to 44,637 units (SEC Form 4) (withholding tax)
- Chief Financial Officer Laponis Adam sold $273,265 worth of shares (1,965 units at $139.07), decreasing direct ownership by 2% to 108,633 units (SEC Form 4) to satisfy tax liability
- Chief Executive Officer Leproust Emily M. sold $923,259 worth of shares (6,639 units at $139.07), decreasing direct ownership by 0.81% to 812,299 units (SEC Form 4) to satisfy tax liability
- SVP of Human Resources Green Paula sold $189,130 worth of shares (1,360 units at $139.07), decreasing direct ownership by 1% to 117,921 units (SEC Form 4) (tax withholding)
- Officer Cho Dennis sold $1,843,099 worth of shares (14,205 units at $129.75) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 75,661 units (SEC Form 4)
- President and COO Finn Patrick John exercised 23,355 shares at a strike of $67.85 and sold $9,217,607 worth of shares (78,355 units at $117.64) as part of a pre-agreed trading plan, decreasing direct ownership by 20% to 214,678 units (SEC Form 4)
- Twist Bioscience Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B7 filed by Twist Bioscience Corporation